A novel interaction between the 5′ untranslated region of the Chikungunya virus genome and Musashi RNA binding protein is essential for efficient virus genome replication.

A novel interaction between the 5′ untranslated region of the Chikungunya virus genome and Musashi RNA binding protein is essential for efficient virus genome replication.

Publication date: Aug 01, 2024

Chikungunya virus (CHIKV) is a re-emerging, pathogenic alphavirus that is transmitted to humans by Aedesspp. mosquitoes-causing fever and debilitating joint pain, with frequent long-term health implications and high morbidity. The CHIKV replication cycle is poorly understood and specific antiviral therapeutics are lacking. In the current study, we identify host cell Musashi RNA binding protein-2 (MSI-2) as a proviral factor. MSI-2 depletion and small molecule inhibition assays demonstrated that MSI-2 is required for efficient CHIKV genome replication. Depletion of both MSI-2 and MSI-1 homologues was found to synergistically inhibit CHIKV replication, suggesting redundancy in their proviral function. Electromobility shift assay (EMSA) competition studies demonstrated that MSI-2 interacts specifically with an RNA binding motif within the 5′ untranslated region (5’UTR) of CHIKV and reverse genetic analysis showed that mutation of the binding motif inhibited genome replication and blocked rescue of mutant virus. For the first time, this study identifies the proviral role of MSI RNA binding proteins in the replication of the CHIKV genome, providing important new insight into mechanisms controlling replication of this significant human pathogen and the potential of a novel therapeutic target.

Open Access PDF

Concepts Keywords
Efficient Binding
Genetic Chikungunya
Host Chikv
Untranslated Demonstrated
Virus Depletion
Efficient
Genome
Motif
Msi
Musashi
Proviral
Region
Replication
Untranslated
Virus

Semantics

Type Source Name
disease MESH morbidity
disease MESH joint pain
drug DRUGBANK Coenzyme M
disease MESH Venezuelan equine encephalitis
disease MESH Rhabdomyosarcoma
disease MESH hepatoma
drug DRUGBANK Peracetic acid
drug DRUGBANK Amino acids
drug DRUGBANK Trypsin
drug DRUGBANK Edetic Acid
drug DRUGBANK Tretamine
disease MESH infection
drug DRUGBANK Dimethyl sulfoxide
drug DRUGBANK Methylergometrine
drug DRUGBANK Glutamic Acid
drug DRUGBANK Puromycin
disease MESH dissociation
drug DRUGBANK Ampicillin
drug DRUGBANK Isopropyl beta-D-thiogalactopyranoside
drug DRUGBANK Lysozyme
drug DRUGBANK Flunarizine
drug DRUGBANK Sodium lauryl sulfate
drug DRUGBANK Glycerin
drug DRUGBANK Albendazole
drug DRUGBANK Aspartame
drug DRUGBANK Esomeprazole
drug DRUGBANK ATP
drug DRUGBANK Cysteamine
disease MESH virus infection
disease MESH Hepatitis
disease MESH alphavirus infection
disease MESH chikungunya virus infection
disease MESH Allergy
pathway KEGG Viral replication
disease MESH triple negative breast cancer
drug DRUGBANK Chloride ion
disease MESH acute myeloid leukemia
pathway KEGG Acute myeloid leukemia

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *